机译:高卵巢癌延长临床临床型有效反应后延长临床临床型高响应性耐受抗病性抗原性口服拓淀粉化疗的抵抗力分析
Biological Sciences Platform S-217 Sunnybrook Research Institute 2075 Bayview Ave. Toronto ON;
Biological Sciences Platform S-217 Sunnybrook Research Institute 2075 Bayview Ave. Toronto ON;
Biological Sciences Platform S-217 Sunnybrook Research Institute 2075 Bayview Ave. Toronto ON;
Biological Sciences Platform S-217 Sunnybrook Research Institute 2075 Bayview Ave. Toronto ON;
National Research Council of Canada Human Health Therapeutics NRCC Montreal QC Canada;
Biological Sciences Platform S-217 Sunnybrook Research Institute 2075 Bayview Ave. Toronto ON;
National Research Council of Canada Human Health Therapeutics NRCC Montreal QC Canada;
National Research Council of Canada Human Health Therapeutics NRCC Montreal QC Canada;
National Research Council of Canada Human Health Therapeutics NRCC Montreal QC Canada;
Biological Sciences Platform S-217 Sunnybrook Research Institute 2075 Bayview Ave. Toronto ON;
Chemotherapy; Metastasis; Ovarian cancer; Pazopanib; Resistance; Topotecan;
机译:晚期卵巢癌临床前长期有效反应后对节律性口服拓扑替康化疗加帕唑帕尼获得性耐药的分析
机译:节律性小剂量口服拓扑替康联合抗血管生成药物帕唑帕尼治疗卵巢癌的临床前效果显着。
机译:低剂量,延长口服拓扑替康治疗晚期卵巢癌,输卵管癌或原发性腹膜浆液性癌的患者的可行性研究,这些患者在铂类化疗后已获得完全的临床反应。
机译:卵巢癌手术治疗45例及腹膜内化疗分析
机译:高温腹膜内化疗的演变在晚期卵巢癌的环境中
机译:晚期卵巢癌临床前长期有效应答后对节律性口服拓扑替康化疗加帕唑帕尼获得性耐药的分析
机译:晚期卵巢癌临床前长期有效应答后对节律性口服拓扑替康化疗加帕唑帕尼获得性耐药的分析